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1  | PRECLINIC AL AND 
CLINIC AL CONCORDANT HE ART 
XENOTR ANSPL ANTATION
The first heart replacement in humans was a xenograft. On January 
23,	 1964,	 James	 Hardy	 (1918-2003)	 from	 Mississippi,	 USA,	 re-
moved the heart of a dying 68-year-old adult and replaced it with 
the	organ	of	a	small	chimpanzee.	After	90	minutes,	the	transplant	
stopped beating, because it was of course too small.1	Hardy	was	
heavily criticized by both the public and his medical peers—partly 
unfair since he and his team had prepared the intervention care-
fully over years; he should, however, have selected a better first 
recipient.
Next	 was	 Christiaan	 Barnard	 (1922-2001)	 from	 Cape	 Town,	
South	Africa.	In	1973,	he	used	a	baboon	and	a	chimpanzee	heart	in	
two	patients	who	were	in	desperate	need	of	a	new	organ	(in	those	
apartheid times, white recipients were only allowed transplants 
from the same skin color—at that time a cause of organ shortage in 
South	Africa).	Due	to	the	size	mismatches	of	the	organs	(recipients	
vs	donors),	Barnard	wisely	used	his	piggyback-technique,	leaving	the	
patient's	heart	in	place	and	using	the	small	transplants	as	(possibly	
temporary)	support	until	a	human	organ	would	eventually	be	avail-
able.	However,	both	recipients	died	early:	the	baboon	organ	failed	
within hours, and the recipient of the chimpanzee heart died after 
4 days.2,3
The	interventions	should	have	been	more	successful.	A	convinc-
ing explanation was not given; the two interventions also created a 
great stir within the community of the university, a reaction which 
Barnard left unmentioned.
At	the	Ludwig-Maximilians	University	in	Munich,	Walter	Brendel	
(1922-1989)	 became	 Head	 of	 the	 Department	 of	 Experimental	
Surgery	 (now	 the	 “Walter	 Brendel	 Center	 for	 Experimental	
Medicine”).	During	most	of	the	1960s	till	the	first	half	of	the	1980s,	
xenotransplantation remained one of his main interests—and that 
of	his	consultant	and	chief	investigator	Claus	Hammer	(1940-2015).	
The	 latter	characterized	preformed	natural	 antibodies	 (PNABs)4 in 
sera of 48 species from seven zoological orders and investigated 
more than 8300 combinations of serum samples and antigens of 
111	individuals.	Among	others,	his	key	finding	was	that	PNABs	were	
absent	or	low	between	the	species	within	a	zoological	family	(con-
cordant	systems)	such	as	domestic	dogs,	foxes	and	dingos;	domestic	
cats,	lions,	and	tigers;	and	man	and	old	world	monkeys.	Heterotopic	
intrathoracic	 fox-to-dog	 heart	 transplants	 remained	 beating	 (but	
not	 working)	 for	 an	 average	 of	 20	 days	 using	 cyclosporine	 and	
cortisone.5,6
In	 contrast,	 PNABs	 were	 augmented	 across	 divergent	 species	
(discordant	systems);	corresponding	experiments	yielded	discourag-
ing results since the grafts never functioned longer than a few hours, 
in spite of aggressive additional treatments with either lymphatic 
drainage or plasmapheresis.7
Both	Brendel	and	Hammer	were	therefore	convinced	“that	con-
cordant non-human primate to human xenotransplantation would 
ultimately become a clinical reality,” but in their opinion, discordant 
procedures would remain unrealistic. They did, however, concede 
that if it ever became feasible it would revolutionize medicine.8
At	approximately	the	same	time,	Leonard	Bailey	(1942-2019)	from	
Loma	Linda,	USA	had	transplanted	Baby	Fae,	a	premature	newborn	
patient	with	hypoplastic	 left	 heart	 syndrome.	 She	barely	 survived	
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on	her	right	heart	only	which	was	connected	to	the	(left)	systemic	
circulation via a huge atrial septum defect and a patent Botalli duct; 
the left heart, after which the syndrome is named, was minute as 
were the mitral and aortic valves, the ascending aorta and the arch. 
At	that	time,	heart	transplantation,	including	the	replacement	of	the	
whole	aortic	arch,	was	considered	the	only	option	(it	is	important	to	
mention that newborns with such a cardiac malformation have usu-
ally no further congenital lesions; in particular the brain is well de-
veloped).	Unable	to	get	a	human	donor	in	time,	Bailey	transplanted	a	
histocompatible	baboon	heart	on	October	10,	1984.	Baby	Fae,	who	
was blood group O, succumbed after three weeks to disseminated 
hemagglutination: The baboon had been blood group incompatible; 
all	six	donors	which	were	available	to	Bailey	were	blood	group	AB.9,10
Bailey	never	did	another	baboon-to-human	transplant.	As	a	mat-
ter of fact, he did not have to, since the reaction to this one and only 
xenogeneic intervention was unexpected: suddenly Bailey received 
human	donors	of	suitable	sizes	from	all	over	North	America,	and	his	
pediatric cardiac transplant program took the lead worldwide.11
In the second half of the 1980s, a similar program was set up 
at	 the	 University	 of	 Cape	 Town,Medical	 School	 (following	 the	 ad-
vice	of	Brendel	and	Hammer;	the	latter	and	Bailey	were	guests	of	a	
Capetonian meeting commemorating the 20th anniversary of the first 
human	heart	transplant	in	1987;	Figure	1).	An	experimental	program	
was set up, transplanting green vervet monkey hearts heterotopically 
into the neck of recipient baboons.12,13 Various immunosuppressive 
regimens were tested; the combination of anti–thymocyte-globulin, 
methylprednisolone, azathioprine, and cyclosporine proved best, with 
the	hearts	beating	(but	not	working)	for	up	to	83	days.
The	 results	 of	 the	 experimental	 study	 quickly	 became	 a	 clin-
ical reality when two babies were referred to the Department of 
Cardiac	Surgery	in	the	Red	Cross	Children's	Hospital,	both	present-
ing	with	hypoplastic	left	heart	syndromes.	After	the	parents	agreed	
to	the	xenotransplantation	(actually	not	a	very	difficult	discussion),	
two captive-bred, blood group-compatible baboons with known 
microorganisms	 were	 ordered	 from	 the	 South	 African	 Medical	
Research Council.14 The preparations for the transplants came to a 
sudden halt when one morning both donors were found dead in their 
cages. No causes were identified, but the message was clear: The 
University	and	the	South	African	society	did	not	want	concordant	
xenotransplantation.
To finish the story, both potential recipients died soon thereaf-
ter, one from pneumonia and the other from cerebral bleeding.
2  | COMMENCING PRECLINIC AL 
DISCORDANT C ARDIAC 
XENOTR ANSPL ANTATION IN NON-HUMAN 
PRIMATES
At	the	end	of	his	Capetonian	time,	DKC	Cooper	conducted	some	
stimulating experiments: after first perfusing porcine wild-type 
kidneys with recipient baboon blood, and thereby removing pre-
formed	 xenogeneic	 antibodies,	 subsequent	 wild-type	 porcine	
heart transplants avoided hyperacute rejection and beat signifi-
cantly longer when compared to control; the porcine hearts were 
connected to the neck vessels of the baboons,1,2,4,15 and cyclo-
sporine and methylprednisolone were given. These experiments 
were a proof of principle that discordant cardiac xenotransplanta-
tion would be possible when natural preformed antibodies could 
be deleted.
In	 the	 early	 1990s,	David	White	 (1946-2017)	 started	 generat-
ing transgenic pigs expressing the human complement regulatory 
protein	hDAF	(decay-accelerating	factor,	hCD55).18	His	first	animal,	
Astrid,	was	 born	 in	December	 1992	 (David	White	 always	 claimed	
it	was	the	25th).	Not	much	later,	he	 invited	Claus	Hammer	and	his	
Munich group to Cambridge and Immutran/Novartis for a week's 
cooperation	 to	 perfuse	 extracorporal	 hearts	 (livers	 and	 kidneys)	
of	 five	 DAF-animals	 with	 human	 blood	 (with	 three	 of	 Hammer's	
perfusion machines; the German researchers served also as blood 
donors).8	The	15	experiments	documented	the	prevention	of	hyper-
acute rejections.18-20 In 1997, The Lancet declared these results the 
ground-breaking achievement of the year.
F I G U R E  1  Participants	of	the	meeting	
commemorating the 20th anniversary 
of the first human heart transplantation, 
Cape Town, 1987; Leonhard Bailey first 
row,	second	from	the	right;	Claus	Hammer	
in the middle, second row
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Everyone in the field became excited and long-term results were 
achieved	 in	 the	 abdominal	 heterotopic	 position	 (the	 heart	 trans-
plants were attached to the abdominal infrarenal aorta, to the in-
ferior vena cava; 21 reviewed in15).	Fundamental	ethical	issues	were	
thoroughly discussed22,23	 and	 in	2000,	 an	Advisory	Committee	of	
the	International	Society	for	Heart	and	Lung	Transplantation	was	set	
up,	which	proposed	its	now	famous	efficacy	recommendations	(not	
guidelines)	for	future	clinical	cardiac	applications:	60%	success	in	a	
consistent group of at least 10 animals. Three months survival was 
suggested for a minimum, but longer periods should be aimed for.24
And	the	xenogeneic	heart	 transplantation	technique	had	to	be	
life supporting. These were ambitious targets in times when me-
dian survival after orthotopic procedures was measured less than 
one	month	(21 also,24,25	the	first	author	M.	Schmoeckel	from	Munich	
University did that study21 during his stay at Immutran/Novartis; the 
cardiac	surgeon	J.	Wallwork	and	D.	White	were	the	senior	authors).
The importance of porcine galactose-α1,3-galactose	 (Gal)	 was	
recognized: Non-antigenic Gal-polymers were given to bind the re-
spective natural Gal-antibodies. In the heterotopic abdominal posi-
tion,	the	grafts	beat	in	baboons	for	a	record	median	of	96	days	(range	
15-137	days).26 These findings would have fulfilled the targets set by 
the	2000	Advisory	Board	only	five	years	before—if	the	results	had	
been achieved in a life-supporting system.
Homozygous	Gal-free	modified	pigs	(GGTA1-KO)	became	avail-
able in the early 2000s.27 Not long thereafter, the first results using 
GGTA1-KO	porcine	hearts	(again	in	the	heterotopic	abdominal	posi-
tion)	were	reported	by	the	Boston	group	which	was	led	by	DH	Sachs	
and	 DKC	 Cooper28: using immunosuppression and co-stimulation 
blockade	 (anti-CD154	 ab),	 the	 median	 survival	 time	 of	 the	 grafts	
amounted	to	78	days	(range	16-179	days).	Myocardial	histology	re-
vealed signs of thrombotic microangiopathy.
In these times, however, the future of xenotransplantation looked 
all	of	a	sudden	grave:	C.	Patience,	Y.	Takeuchi,	and	RA	Weiss	pub-
lished	 their	 influential	 study	 on	 Porcine	 Endogenous	 Retroviruses	
(PERVs)	 and	 potential	 infectious	 risks	 after	 xenogeneic	 proce-
dures.29	 Severe	ethical	 questions	were	 raised	and	even	a	morato-
rium	of	xenogeneic	procedures	was	discussed;	F.	Bach	summarized:	
The	benefits	(and	risks)	of	the	treatment	of	a	terminally	ill	individual	
must be weighed against the collective risk for a whole society.30	As	
a	consequence,	Immutran/Novartis	was	closed,	as	was	the	William	
J.	von	Liebig	defined	pathogen	free	(DPF)	unit	in	Rochester	next	to	
the Mayo Clinic. Well, xenotransplantation survived and 20 years 
thereafter,	RA	Weiss	summarized	without	regrets31:	“If	we	had	not	
investigated	PERVs	in	the	1990s,	we	would	not	have	(eg)	pigs,	free	
from	known	infectious	(microorganisms)	today.”
During these last two decades, safety issues remained one 
of	 the	major	 topics	 in	 the	 field.	No	PERV-infections	were	 seen	 in	
humans.32,33
It is therefore remarkable that these were the times when in 
1998	 preclinical	 discordant	 xenotransplantation	 (using	 non-hu-
man	 primates)	 commenced	 in	 Germany,	 first	 supported	 by	 the	
Bavarian,	 then	 the	German	Research	Foundation.	The	Consortium	
has	 now	 three	 pillars:	 Munich	 (Ludwig-Maximilians	 and	 Technical	
Universities),	 Hannover	 (Medical	 School),	 and	 Dresden	 (Technical	
University).	While	in	Germany,	all	universities	are	funded	by	the	re-
spective	 States,	 it	was	wise	 to	 attach	 four	 Federal	 (German	wide)	
Institutions:	Robert-Koch	(Berlin),	Paul-Ehrlich	(Langen),	Friederich-
Löffler	 (Mariensee),	 and	 the	 German	 Primate	 Center	 (Göttingen).	
Together, this Collaborative Research Center is a consortium of im-
munologists, bioengineers, virologists, primatologists, ethicists, legal 
authorities, and clinicians.
In the first decade of the 21st century, preclinical xenogeneic 
orthotopic	 (life	 supporting)	heart	 transplantation	was	 the	 focus	of	
our Munich cardiosurgical team. The results were, however, incon-
sistent and unpredictable—as they were everywhere else 25,34-41: 
the	survival	rates	in	non-human	primates	ranged	from	1	to	57	days,	
with	 an	 unacceptably	 high	 40%-60%	 perioperative	 mortality,	 al-
though	clinically	approved	heart	preservation	techniques	were	ap-
plied	(after	allogeneic	procedures,	primary	failure	rates	are	four	to	
six	times	lower).	G.	Byrne	and	C.	McGregor	termed	the	phenomenon	
“Perioperative	 Cardiac	 Xenograft	 Dysfunction”	 (PCXD).21,42 They 
concluded	that	PCXD	was	not	a	hyperacute	rejection	reaction,	but	
resembled	more	ischemic	reperfusion	injury	or	the	“old-fashioned”	
cardiac stunning of the early days of heart surgery, when effective 
cardioplegic	techniques	were	not	available.
3  | INTR ATHOR ACIC (LIFE SUPPORTING) 
HETEROTOPIC XENOTR ANSPL ANTATION
Until	2007,	our	 team	 in	Munich	exclusively	used	hDAF-expressing	
donor animals from the previous Immutran/Novartis farm, and 
the	 non-antigenic	 Gal-polymer	 GAS914	 was	 given	 together	 with	
standard immunosuppression.40 During that time, two organs from 
hCD46 transgenic animals were also transplanted orthotopically 
into baboons: The live donors remarkably passed the intercontinen-
tal	borders	between	North	America	and	Germany	without	any	delay	
(the	 animals	originated	 from	 the	William	 J.	 von	Liebig	DPF-unit	 in	
Rochester,	Mn.).
After	 the	 9th	 IXA	 meeting	 in	 Minneapolis,	 2007,	 we	 had	 ac-
cess	 to	 double	 genetically	 modified	 (GGTA1-KO,	 hCD46-tg)	 pigs	
from	D.	Ayares	 (Revivicor,	Blacksburg,	Va.).	 In	cooperation	with	E.	
Wolf	and	his	team	(Molecular	Animal	Breeding	and	Biotechnology,	
Gene-Center; Center for Innovative Medical Models, CiMM, both 
LMU,	Munich),	 human	 thrombomodulin	 (hTBM)	was	 added.43 This 
was the time when intrathoracic heterotopic heart transplantation 
was	 contemplated,	 a	 preclinical	model	 combining	 the	 prerequisite	
of	 a	 life-supporting	 technique	with	 the	 advantages	 of	 two	 hearts	
which	to	various	extents	contributed	to	the	combined	(total)	cardiac	
output: when, for example, immediately after surgery the recipient 
heart may still have to produce the major share in case a transplanted 
organ	is	not	able	to	perform	adequately	due	to	ischemia/reperfusion	
damage. The transplants will then recover after a few days and take 
over	the	brunt	of	the	(combined)	left-sided	ventricular	output.
Intrathoracic heterotopic heart transplantation was clinically 
introduced	 by	 Christiaan	 Barnard	 50	 years	 ago,44,45 whereby the 
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donor organ is placed within the right chest and next to the recipi-
ent	heart.	Four	anastomoses	are	needed:	between	the	left	and	right	
atria, the end-to-side connections of the aortae, and the pulmonary 
arteries	(with	an	interposition	vascular	graft).	Clinical	hemodynamic	
and echocardiographic measurements proved that the transplanted 
heart	made	up	on	average	73%	of	the	total	cardiac	output.46 Long-
term	results	were	good	with	1,	2,	and	5-year(s)	survival	rates	of	63%,	
54%,	and	43%	(therefore	slightly	inferior	when	compared	to	orthot-
opic procedures.47
Twenty-one consecutive experiments were carried out in ba-
boons between 2009 and 2013.48 Using Bretschneider's crystalloid 
HTK	 cardioplegic	 solution,49,50	 PCXD	 was	 not	 seen	 and	 in	 19/21	
cases, the recipients came off cardio-pulmonary bypass without dif-
ficulties	(technical	failures	were	the	cause	of	death	of	the	remaining	
two).	Myeloablative	 induction	 therapy	 like	 that	 used	 for	myeloma	
patients	 (anti-CD20ab,	 Cyclophosphamid,	 ±	 Bortezomib)51 was 
given and immunoglobulin-apheresis added immediately before sur-
gery. Maintenance immunosuppression consisted of anti-CD20ab, 
Tacrolimus,	MMF,	and	steroids.	 In	a	second	group,	 thoracoabdom-
inal lymphoid irradiation with six Grays was added; co-stimulation 
blockade was not available.
Overall	 mean	 survival	 (excluding	 four	 technical	 failures)	 was	
21.7 ±	6	days,	with	the	longest	lasting	for	50	days.	Echocardiography	
showed that mitral and aortic valves opened and closed, proving the 
contribution	of	the	transplant	to	the	cardiac	output	(and	of	course,	
there	 were	 additional	 arterial	 pressure	 curves	 on	 the	 monitor).	
Bacterial	and	fungal	infections	were	common	(at	that	time,	we	had	
to	share	our	operative	room	with	other	groups).	In	the	longer-term	
survivors,	an	excessive	graft	overgrowth	of	more	than	200%	within	
one month was seen, a phenomenon we could not explain. These 
transplants compressed more or less the whole right lung; as a con-
sequence,	the	baboons	had	to	remain	in	an	oxygen	tent	which	en-
closed their cages.
In one case, the donor heart compressed most of the recipient's 
left	atrium	causing	finally	recalcitrant	lung	edema	(Figure	2).	In	this	
context, it should be mentioned that the signs of overgrowth ob-
served in our baboon experiments had never been seen in clinical 
practice	(47,	personal	experience).
Taken together, we concluded that intrathoracic heterotopic 
xenogeneic heart transplantation would be a useful clinical tool 
provided	 an	 immunosuppression	 was	 less	 toxic.	 The	 technique	
may offer advantages, especially under the circumstances of a first 
clinical application followed by an unexpected graft failure. The re-
cipient's own heart could then serve as a back-up until a new trans-
plant—human or preferably porcine—was available.
Intrathoracic heterotopic xenogeneic heart transplantation 
would also be a good solution in patients with severe pulmonary hy-
pertension.	Under	these	circumstances,	the	patient's	own	(adapted)	
right	 ventricle	would	 support	 the	 respective	 (not	 adopted	 to	 high	
pressures)	donor	chamber.46
Right	at	that	time,	M.	Mohiuddin	(NIH,	Bethesda,	USA)	published	
his first results after heterotopic abdominal heart xenotransplanta-
tion	with	the	same	genetically	modified	GGTA1-KO,	hCD46-tg	(	 in	
a	 last	group	plus	hTBM)	Revivicor	donor	hearts,52 using a chimeric 
2C10R4 anti-CD40 antibody, which was available to us after the 11th 
IXA	meeting,	 2011,	 in	Miami	 Beach.	 Two	 successful	 intrathoracic	
heterotopic transplants were done. Thereafter we were however 
forced to change our plans: To fulfill the new European Directive on 
the	Protection	of	Animals	used	for	Scientific	Purposes	and	a	decision	
of	 local	Upper	Bavarian	Authorities,	we	had	to	renovate	our	facili-
ties. In a new operative room, exclusively dedicated to cardiac xe-
notransplantation, orthotopic procedures had to be done by order.
4  | PRECLINIC AL ORTHOTOPIC C ARDIAC 
XENOTR ANSPL ANTATION
In the meantime, M. Mohiuddin had published his milestone achieve-
ment after heterotopic abdominal heart xenotransplantation,53 using 
high	dose	anti-CD40	antibody.	In	a	last	group	(n	=	5),	a	median	graft	
survival	of	298	days	was	achieved,	with	a	maximum	of	945	days.
Our 14 orthotopic experiments, using an immunosuppression 
protocol slightly changed from Mohiuddin's, were performed be-
tween	2015	and	2018.54	Unfortunately,	group	 I	 (n	=	5)	 came	 to	a	
quick	 end:	 using	 clinically	 approved	 crystalloid	 cardioplegic	 solu-
tions,	 survival	 times	were	 one	 day	 (n	=	 3),	 3	 and	 30	 days;	 severe	
systolic	pump	failure	was	diagnosed	in	4	cases	(low	cardiac	output	
despite	high	dosages	of	catecholamines,	the	so-called	“Perioperative	
Cardiac	Xenograft	Dysfunction”	(PCXD)).
PCXD	was	 eliminated	 in	 group	 II	 (n	=	 4)	 after	 we	 introduced	
“Non-ischemic	Porcine	Heart	Preservation.”	 In	cooperation	with	S.	
Steen's	group	from	Lund	University,	Sweden,	the	grafts	were	imme-
diately perfused with a 8°C hyperoncotic cardioplegic solution con-
taining erythrocytes, nutrition, and hormones55	(Figure	3);	perfusion	
was intermittently continued even during implantation. The survival 
times	were	4	(technical	failure),	18,	27,	and	40	days.	The	three	long-
term survivors succumbed to rapidly developing graft overgrowth 
with signs of terminal diastolic pump failure and consecutive liver 
F I G U R E  2  Post-mortem	frontal	view	after	heterotopic	
intrathoracic	pig-to-baboon	heart	transplantation	(porcine	
transplant to the right of the recipient organ; pulmonary end-to-
side	anastomosis	with	interposition	graft	shown):	note	transplant	
overgrowth on post-operative day 19, it was initially smaller than 
the	recipient	heart	(from48; at that time we could not explain the 
phenomenon)
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damage. Detrimental xenograft overgrowth was thought to be in-
trinsic,	that	is,	genetically	determined	(changes	as	for	an	ultimately	
200 kg German Landrace pig, lethal in the small chest of a baboon 
recipient).	Similar	findings	have	been	described	in	pig-to-baboon	kid-
ney transplantation56	(see	also	Figure	2).
In	the	last	group	III	(n	=	5),	cardiac	overgrowth	was	successfully	
counteracted by:
1.	 decreasing	 the	blood	pressure	of	 the	baboons	 (pigs	have	 lower	
blood pressures57),
2. early weaning from Cortisone, which can cause hypertrophic car-
diomyopathy in early human life,58 and
3.	 treatment	 with	 the	 Sirolimus	 prodrug	 Temsirolimus	 to	 inhibit	
growth-hormones by blocking mTOR-kinases.59
Altogether,	one	animal	was	 lost	 to	 recalcitrant	pleural	effusion	
due	to	thoracic	lymph	duct	occlusion.	All	others	survived	long	term:	
two	recipients	for	three	months,	two	others	for	182	and	195	days;	all	
four were euthanized in good general condition.
In the meantime, the group was completed according to the effi-
cacy	requirements	of	the	Advisory	Board	of	the	ISHLT	24,60:	Four	ad-
ditional cases were added of whom two reached the 3 months mark, 
and another two succumbed early to generalized porcine cytomeg-
alovirus	(PCMV)	infections;	PCMV	will	be	avoided	in	the	future	by	
early weaning 61 and finally by animal selection.
Taken together, six out of eight consecutive baboons survived 
orthotopic xeno-heart transplantation for at least three months, ex-
ceeding	the	threshold	set	by	the	Advisory	Board.
5  | OUTLOOK
What remains to be done before entering the clinical scenario 
of	 a	 pilot	 study?	 According	 to	 a	 first	 scientific	 advice	 by	 the	
Innovation	Office	of	the	Paul-Ehrlich	Institute	(the	German	rep-
resentative	of	the	European	Medicines	Agency,	EMA),	regulatory	
requirements	 will	 not	 be	 unsurmountable—but	 they	 will,	 how-
ever,	 take	time.	Additional	gene	modifications	might	be	helpful,	
like hCD4762	or	PD-L163;	the	question	of	the	ideal	co-stimulation	
blockade will have to be answered.64,65	 And	 last	 but	 not	 least,	
the size/growth of a donor organ will matter, especially in smaller 
recipients.54,66
Dealing	with	 the	 PERV-issue—two	 solutions	 are	 now	 available	
and widely accepted:
1.	 selecting	PERV-C-free	donor	animals	to	avoid	A/C	recombinants	
which have a high replication rate in infected human cells67-69; 
also	 the	 virus	 load	 of	 PERV	 A	 and	 B	 should	 be	 low.
2.	 generation	of	healthy	pigs	without	PERVs	using	CRISPR/Cas	tech-
nology, as demonstrated by eGenesis, Boston.70,71
Since	both	strategies	are	clinically	acceptable,	cost,	and	afford-
ability might be a crucial point.
And	 finally	 the	 advice	of	Weiss31:	 “While	 the	promise	of	 clini-
cal xeno-transplantation once again looks very bright, disregard to 
infectious risks, we know we must not relapse into complacency.”
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